Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.

Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

Musk revealed using Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, highlighting their popularity for weight management.

The drug was launched in the U.S. back in 2023 to treat obesity.

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

This time last year, people were still bickering about whether Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound represented a shortcut to losing weight or a medical breakthrough. But with reams of ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...